Effect of Topical Prostaglandin Analogue Therapy on Central Corneal Thickness: A Systematic Review.
Jae-Yun KimHyeon-Woo YimPublished in: Journal of clinical medicine (2022)
To investigate whether prostaglandin analogue (PGA) eyedrops have a significant effect on central corneal thickness (CCT), we conducted a systematic search of literature published from 2000 to 2021. Among the studies conducted on topical PGA therapy in open-angle glaucoma or ocular hypertension patients over 18 years old, prospective studies with CCT change as an outcome were included. A single-arm meta-analysis was conducted to assess the overall effect on CCT, and subgroup analysis according to exposure time of PGA eyedrops was also performed. We counted the number of articles that reported on severe events (CCT reduction of 25 μm or more) and obtained their proportion. The methodological quality was assessed by the McHarm tool. Twenty-two reports of prospective studies were selected. The results of the single-arm meta-analysis showed very high heterogeneity. Still, in subgroup analysis, when PGA was used for more than 6 months, heterogeneity was low, and a significant decrease in CCT was observed. Severe events were reported in two reports and occurred in 3.8% to 14.8% of participants. PGA eyedrop use may cause a clinically significant CCT decrease, requiring CCT follow-up.
Keyphrases
- systematic review
- case control
- optical coherence tomography
- meta analyses
- wound healing
- end stage renal disease
- blood pressure
- early onset
- ejection fraction
- chronic kidney disease
- single cell
- emergency department
- stem cells
- adverse drug
- prognostic factors
- clinical trial
- peritoneal dialysis
- study protocol
- phase iii
- open label
- data analysis